Table 2. Changes in Voiding Frequency and Other Urinary Symptoms .
Bladder Diary Variable | Mean (SD) | P Value | ||
---|---|---|---|---|
Behavioral Therapy (n = 71) | Drug Therapy (n = 68) | Combined Therapy (n = 65) | ||
After 6-wk Follow-up (Stage 1) | ||||
Mean 24-h voiding frequency, voids/d | ||||
Baseline | 11.7 (2.4) | 11.8 (2.5) | 11.8 (2.4) | >.99 |
Posttreatment | 8.8 (2.1) | 10.3 (2.7) | 8.2 (2.3) | <.001a |
Change (baseline to 6-wk follow-up) | 2.9 (2.4) | 1.5 (2.3) | 3.6 (2.1) | <.001a |
Change, % | 24.7 | 12.7 | 30.5 | NA |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean nocturia frequency, episodes/nightc | ||||
Baseline | 2.1 (1.2) | 2.2 (1.1) | 2.1 (1.3) | .85 |
Posttreatment | 1.3 (0.8) | 1.8 (1.2) | 1.3 (1.0) | <.001a |
Change (baseline to 6-wk follow-up) | 0.7 (1.0) | 0.4 (1.0) | 0.9 (1.1) | <.001a |
Within-group P valueb | <.001 | .004 | <.001 | NA |
Mean urgency scored | ||||
Baseline | 1.6 (0.6) | 1.6 (0.5) | 1.5 (0.6) | .40 |
Posttreatment | 1.6 (0.6) | 1.5 (0.5) | 1.3 (0.7) | .004a |
Change (baseline to 6-wk follow-up) | −0.1 (0.5) | 0.1 (0.5) | 0.2 (0.6) | .004a |
Within-group P valueb | .19 | .10 | .03 | NA |
Maximum urgency scored | ||||
Baseline | 2.3 (0.7) | 2.4 (0.6) | 2.4 (0.6) | .70 |
Posttreatment | 2.2 (0.7) | 2.2 (0.6) | 1.8 (0.8) | <.001a |
Change (baseline to 6-wk follow-up) | 0.1 (0.6) | 0.2 (0.6) | 0.5 (0.7) | <.001a |
Within-group P valueb | .14 | .002 | <.001 | NA |
Incontinence, episodes/wk | ||||
Baseline | 6.8 (11.3) | 5.5 (10.4) | 6.6 (10.1) | .78 |
Posttreatment | 3.1 (6.0) | 2.6 (6.6) | 1.5 (4.3) | .15a |
Change (baseline to 6-wk follow-up) | 3.6 (8.0) | 2.9 (10.6) | 5.2 (8.9) | .15a |
Change, % | 52.9 | 52.7 | 78.8 | NA |
Within-group P valueb | <.001 | .03 | <.001 | NA |
Mean Overactive Bladder Questionnaire score | ||||
Baseline | 65.5 (34.0) | 61.1 (32.4) | 62.6 (34.8) | .74 |
Posttreatment | 43.0 (28.2) | 39.5 (30.0) | 23.8 (22.1) | <.001a |
Change (baseline to 6-wk follow-up) | 22.5 (22.0) | 21.6 (27.6) | 38.8 (31.3) | <.001a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean International Prostate Symptom Scoree | ||||
Baseline | 15.9 (5.5) | 16.3 (5.9) | 17.6 (6.4) | .21 |
Posttreatment | 11.4 (5.3) | 11.5 (5.8) | 9.2 (4.8) | <.001a |
Change (baseline to 6-wk follow-up) | 4.6 (4.1) | 4.7 (5.9) | 8.5 (4.9) | <.001a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
After 12-wk Follow-up (Stage 2) | ||||
Mean 24-h voiding frequency, voids/d | ||||
Baseline | 11.7 (2.4) | 11.8 (2.5) | 11.8 (2.4) | >.99 |
12-wk treatment | 8.0 (2.2) | 8.6 (2.3) | 8.0 (2.2) | .33a |
Change (baseline to 12-wk follow-up) | 3.7 (2.3) | 3.2 (2.5) | 3.8 (2.1) | .33a |
Change, % | 31.6 | 27.1 | 32.2 | NA |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean nocturia frequency, episodes/nightc | ||||
Baseline | 2.1 (1.2) | 2.2 (1.1) | 2.1 (1.3) | .85 |
12-wk treatment | 1.2 (0.9) | 1.4 (1.1) | 1.2 (1.0) | .34a |
Change (baseline to 12-wk follow-up) | 0.9 (1.0) | 0.8 (1.0) | 1.0 (1.0) | .34a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean urgency scored | ||||
Baseline | 1.6 (0.6) | 1.6 (0.5) | 1.5 (0.6) | .40 |
12-wk treatment | 1.5 (0.6) | 1.5 (0.6) | 1.2 (0.7) | .06a |
Change (baseline to 12-wk follow-up) | 0.1 (0.6) | 0.2 (0.6) | 0.3 (0.6) | .06a |
Within-group P valueb | .34 | .06 | .002 | NA |
Maximum urgency scored | ||||
Baseline | 2.3 (0.7) | 2.4 (0.6) | 2.4 (0.6) | .70 |
12-wk treatment | 2.0 (0.8) | 2.0 (0.8) | 1.8 (0.8) | .07a |
Change (baseline to 12-wk follow-up) | 0.3 (0.7) | 0.4 (0.7) | 0.6 (0.8) | .07a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Incontinence, episodes/wk | ||||
Baseline | 6.8 (11.3) | 5.5 (10.4) | 6.6 (10.1) | .78 |
12-wk treatment | 1.2 (2.5) | 1.1 (3.0) | 1.2 (3.1) | >.99a |
Change (baseline to 12-wk follow-up) | 5.5 (10.0) | 4.4 (10.1) | 5.4 (9.1) | >.99a |
Change, % | 80.9 | 80.0 | 81.8 | NA |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean Overactive Bladder Questionnaire score | ||||
Baseline | 65.5 (34.0) | 61.1 (32.4) | 62.6 (34.8) | .74 |
12-wk treatment | 22.8 (21.9) | 26.4 (24.5) | 18.9 (18.6) | .11a |
Change (baseline to 12-wk follow-up) | 42.7 (29.9) | 34.7 (29.6) | 43.7 (33.6) | .11a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Mean International Prostate Symptom Scoree | ||||
Baseline | 15.9 (5.5) | 16.3 (5.9) | 17.6 (6.4) | .21 |
12-wk treatment | 8.2 (5.3) | 8.8 (4.7) | 8.0 (4.8) | .32a |
Change (baseline to 12-wk follow-up) | 7.7 (5.3) | 7.5 (5.9) | 9.6 (5.6) | .32a |
Within-group P valueb | <.001 | <.001 | <.001 | NA |
Abbreviation: NA, not applicable.
F test adjusting for baseline values and age.
Within-group P value compared baseline vs posttreatment, ie, treatment effects, with Wilcoxon signed rank sum test.
Nocturia was defined as the number of voids between the time the participant went to bed with the intention of sleeping and just prior to morning awakening (as recorded in the diary).
Scores ranged from 0 to 3, with 0 indicating none (no urgency); 1, mild (awareness of urgency but is easily tolerated); 2, moderate (enough urgency discomfort that it interferes with or shortens usual activity); and 3, severe (extreme urgency discomfort that abruptly stops all activities or tasks).
Scores ranged from 0 to 35, with higher scores indicating more frequent lower urinary tract symptoms.